Non-small-cell lung cancer (NSCLC ... begins in the alveoli (the tiny air sacs in the lungs), called adenocarcinoma in situ (AIS), previously known as bronchioloalveolar carcinoma.

I want my family to understand our shared cancer risks, but I sometimes struggle to face the painful reality of the disease ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

The objective of this study was to assess whether adding CAN-2409 in combination with the prodrug valacyclovir to standard of care radiation therapy could improve the proportion of patients achieving ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...

Lung carcinoma is the most commonly diagnosed cancer and the leading cause of cancer deaths in the US. It accounts for 12% of all cancers diagnosed worldwide, making it the most common malignancy ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

To assess malignancy risk, researchers reviewed all CT scans performed as part of a lung cancer screening programme between ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its research abstracts have been accepted for poster ...